抗真菌疗法对阿斯伯吉路斯种类的抗真菌疗法. : 现在和未来
1Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan.
Seminars in respiratory and critical care medicine
|December 27, 2023
概括
目前的肺性阿斯伯吉洛症治疗有局限性. 新型抗真菌药物正在开发中,为抗耐药真菌感染提供更安全,更有效的口服疗法提供了潜力.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺部阿斯伯吉洛症的治疗方法,包括阿佐尔,赤甘和安福特里辛B,面临着毒性,药物相互作用和耐药性等挑战.
- 现有的疗法存在重大局限性,导致阿斯伯吉洛症的大量发病率和死亡率.
- 迫切需要新的,安全的,口服生物可用的治疗方法,具有有利的药理动力学和对抗耐药菌株的活性.
研究的目的:
- 审查目前肺部阿斯伯吉洛症的治疗选择,并强调需要新的治疗策略.
- 讨论正在开发的新型抗真菌药物的管道,用于侵入性阿斯伯吉洛症.
- 评估新兴疗法的潜力,以解决现有治疗方法的局限性.
主要方法:
- 对肺部阿斯伯吉洛症的当前和试验性治疗方法的文献评论.
- 对新型抗真菌剂的局限性和潜在益处的分析.
- 评估新的阿斯珀吉洛症疗法临床开发的现状.
主要成果:
- 目前的治疗方法 (triazoles, echinocandins, amphotericin B) 有显著的局限性,包括毒性,耐药性和未经证实的疗效.
- 新型药物如雷扎金,伊布雷克萨格尔普,吸入的奥佩尔科纳,口服安福特里辛B,奥洛菲姆和福斯曼诺杰皮克斯显示出有前景.
- 这些试验性疗法有可能提高安全性,口服生物可用性和对抗耐药真菌菌株的活性.
结论:
- 由于当前治疗方法的局限性,对改善肺性阿斯伯吉洛症治疗存在重大未满足的需求.
- 一个强大的新型抗真菌剂的管道正在出现,有潜力克服现有的治疗挑战.
- 虽然有前途,但这些新型药物需要进一步进行强有力的临床研究,特别是III期试验,以确定它们在治疗阿斯伯吉洛症中的疗效和安全性.
相关概念视频
01:28Fungal Phylum Microsporidia
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
01:28Fungal Phylum Ascomycota
Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...